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oving Beyond Angiotensin II
o Also Target Aldosterone?*
illiam C. Little, MD, Paul M. Kirkman, MD
inston-Salem, North Carolina
he renin-angiotensin-aldosterone system plays an impor-
ant role in the development and progression of cardiovas-
ular disease. Initial therapeutic interventions focused on
ngiotensin II, whose production from angiotensin I can be
educed by angiotensin-converting enzyme (ACE) inhibi-
ors or whose action can be inhibited through the use of
ngiotensin receptor blockers (ARBs) (1).
See page 505
Angiotensin II is a vasoconstrictor and stimulates the
roduction of aldosterone by the adrenals (2). Both angio-
ensin II and aldosterone stimulate volume retention, ven-
ricular hypertrophy, and fibrosis (ventricular, vascular, and
enal) as well as systemic inflammation and coagulation.
educing the generation or action of angiotensin II with
CE inhibitors and ARBs is effective in treating arterial
ypertension (3), improving outcome in patients with re-
uced left ventricular ejection fraction (4), decreasing the
evelopment of diabetes (5), slowing the progression of
ascular disease (6), and protecting renal function (7). Thus,
CE inhibitors and ARBs play an important role in the
reatment and prevention of cardiovascular disease by re-
ucing the adverse consequences of angiotensin II and
ldosterone. More recently, aliskiren has been used to block
he action of renin, the most proximal step in the produc-
ion of angiotensin II and subsequently aldosterone (8).
It is important to recognize that angiotensin II is not the
nly stimulus for the production of aldosterone. An increase
n serum potassium is a strong stimulant of adrenal produc-
ion of aldosterone. Other potential stimuli of aldosterone
nclude catecholamines, endothelin, and arginine vasopres-
in (9). Substantial levels of aldosterone may be present even
n the presence of an ACE inhibitor (10). These observa-
ions suggest that blocking the effects of aldosterone could
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of the JACC or the
merican College of Cardiology.
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yers Squibb, CorAssist Cardiovascular, Ltd., Celladon Corporation, Boston Sci-
ntific, Medtronic, Bio-Control Medical, CVRx, and CV Therapeutics.rovide benefit when added to an ACE inhibitor or ARB.
here is already substantial support for this concept. For
xample, aldosterone blockers have additional benefits when
dded to ACE inhibitors in selected patients with heart
ailure (11) and in ventricular dysfunction after myocardial
nfarction (12).
The study of patients with mild chronic renal impairment
rom Birmingham University in the United Kingdom (13),
ublished in this issue of the Journal, extends these obser-
ations. The authors of this study found that the addition of
he aldosterone blocker spironolactone for 36 weeks pro-
uced a clear reduction in left ventricular mass and aortic
tiffness. These benefits occurred in patients who were
lready being treated with an ACE inhibitor or an ARB and
ad well-controlled blood pressure (130/85 mm Hg).
Patients with chronic kidney disease (CKD) have a
arkedly increased risk of cardiovascular disease, which
ncreases as the glomerular filtration rate decreases (14).
ven patients with mild renal dysfunction have an increased
ardiovascular risk. Both left ventricular hypertrophy and
ncreased arterial stiffness are powerful risk factors for
ardiovascular disease in the general population and in
atients with renal dysfunction. The present study shows
hat aldosterone has an important role in regressing left
entricular hypertrophy and reducing increased arterial stiff-
ess in CKD. These findings suggest that aldosterone
lockade with spironolactone may be effective in reducing
he risk of cardiovascular disease in these patients. It is
mportant to recognize that although left ventricular hyper-
rophy and arterial stiffness are strong markers of increased
ardiovascular risk, they may not be the mechanism of all of
he risk (15). Thus, the benefit of aldosterone on clinical end
oints needs to be directly investigated.
Aldosterone blockade may have a role in the treatment of
eart failure associated with a preserved ejection fraction
0.50). There is no specific therapy that has been shown to
e of benefit beyond the control of hypertension (16,17).
ecause left ventricular hypertrophy, fibrosis, and increased
rterial stiffness may play an important role in the patho-
enesis of this disorder, aldosterone is a very attractive
herapeutic target. For these reasons, spironolactone is
eing investigated as a therapy for these patients in an
ngoing large multicenter trial sponsored by the National
nstitutes of Health (TOPCAT [Therapy in Adults With
reserved Ejection Fraction Congestive Heart Failure]).
Treatment with spironolactone produced a significant
ecrease in albuminuria in the Birmingham study, sug-
esting that it has a renal protective effect beyond the use
f an ACE inhibitor or ARB. However, it should be
oted that treatment with an ARB in addition to an ACE
nhibitor may decrease albuminuria, but not result in
enal protection (18).
Aldosterone stimulates renal excretion of potassium.
hus, blocking aldosterone’s actions may result in hyperka-
emia, especially in patients with renal dysfunction who are
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Aldosterone August 4, 2009:513–4lso receiving an ACE inhibitor or ARB. For example, after
he publication of the RALES (Randomized Aldactone
valuation Study) study, in which the authors demonstrated
n improved survival in patients with heart failure and a
educed ejection fraction treated with spironolactone, there
as an abrupt increase in the occurrence of serious hyper-
alemia in such patients in Canada (19). It is important to
ecognize that the patients in the Birmingham study under-
ent a 4-week, open-label, run-in phase of 25 mg of
pironolactone daily before they were randomized to con-
inue with spironolactone or placebo for the following 36
eeks (13).
During this run-in period, 1 patient was withdrawn
ecause of serious hyperkalemia (6.5 mmol/l). In addition, 6
atients (5%) had potassium levels between 5.5 and 5.9
mol/l during the run-in phase and, thus, were switched to
eceive spironolactone on alternate days. During the blinded
reatment phase of the study, 4 patients had potassium levels
etween 5.5 and 5.9 mmol/l and required a dose reduction.
urthermore, serum potassium was greater in the spirono-
actone group than the placebo group at the end of the study
4.6 mmol/l vs. 4.4 mmol/l). This study and the previous
bservations (11,12) demonstrate that patients with mild
enal insufficiency can tolerate spironolactone in addition to
n ACE inhibitor, but their serum potassium must be
arefully monitored.
The renin-angiotensin-aldosterone system is an impor-
ant therapeutic target for the treatment and prevention of
ardiovascular disease. The use of ACE inhibitors and
RBs has been an important therapeutic advance. Increas-
ng observations suggest that aldosterone blockers have the
otential to provide additional benefit (9–13). This has
een proven in selected patients with systolic heart failure
nd patients with substantial left ventricular dysfunction
fter myocardial infarction, is being investigated in patients
ith heart failure with preserved ejection fraction, and the
irmingham study indicates it should be studied in patients
ith CKD.
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